Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Press Releases
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société SANOFI
03:10aTop Intellectual Property Issues To Watch In 2022
AQ
12/06VACCINES INVESTOR EVENT : Sanofi reiterates confidence in strong growth outlook and showca..
PU
12/06SANOFI : EMA accepts regulatory submission for olipudase alfa, the first potential therapy..
PU
12/06Success For Sanofi And Rouse
AQ
12/02Vaccines Investor Event, Sanofi reiterates confidence in strong growth outlook and show..
AQ
12/01VACCINES INVESTOR EVENT : Sanofi reiterates confidence in strong growth outlook and showca..
AQ
12/01Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based ..
AQ
11/22SANOFI : invests $180 million equity in Owkin's artificial intelligence and federated lear..
PU
11/18Sanofi invests $180 million equity in Owkin's artificial intelligence and federated lea..
AQ
11/15Sanofi announces results of CHMP re-examination of the New Active Substance status for ..
AQ
11/12Sanofi announces results of CHMP re-examination of the New Active Substance status for ..
PU
11/11District Courts Issue Key Decisions In 340B Contract Pharmacy Cases
AQ
11/09Sanofi completes acquisition of Kadmon - Form 6-K
PU
11/09Sanofi completes acquisition of Kadmon
AQ
11/04New data in blood cancers, hemophilia, and other hematological disorders to be presente..
PU
10/29Libtayo® (cemiplimab) approved in Canada for locally advanced basal cell carcinoma (BCC..
AQ
10/28SANOFI : Q3 Earnings Snapshot
AQ
10/28SANOFI : Strong Q3 performance drives guidance upgrade to around 14% business EPS growth a..
GL
10/26Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate sign..
PU
10/25REGENERON PHARMACEUTICALS : Second dupixent (dupilumab) phase 3 eosinophilic esophagitis t..
AQ
10/22SANOFI : Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin..
AQ
10/21REGENERON PHARMACEUTICALS : Fda expands approval of dupixent (dupilumab) to include childr..
AQ
10/15SANOFI : New long-term data reinforcing promising safety and efficacy profile of brain-pen..
PU
10/13SANOFI : Update from Sanofi regarding Kevzara (sarilumab) - Supply constraints anticipated..
AQ
10/13SANOFI : New long-term data reinforcing promising safety and efficacy profile of brain-pen..
AQ
10/12UPDATE FROM SANOFI REGARDING KEVZARA : Supply constraints anticipated until early 2022
PU
10/08SANOFI : - Positive results from the first study of high-dose influenza vaccine with a COV..
AQ
10/07SANOFI : New, late-breaking data at EADV highlights emerging clinical profile of amlitelim..
PU
10/07SANOFI : Positive results from the first study of high-dose influenza vaccine with a COVID..
PU
10/04SANOFI : Enthera Pharmaceuticals Enthera Pharmaceuticals appoints Antonio Speziale as Chie..
AQ
10/01SANOFI : - New, late-breaking data at EADV highlights emerging clinical profile of amlitel..
AQ
09/30SANOFI : New, late-breaking data at EADV highlights emerging clinical profile of amlitelim..
AQ
09/30SANOFI : announces positive Phase 1/2 study interim results for its first mRNA-based vacci..
PU
09/28SANOFI : to focus its COVID-19 development efforts on the recombinant vaccine candidate
PU
09/28SANOFI : - New research presented at IDWeek 2021 reinforces Sanofi :'s robust vaccines pip..
AQ
09/28SANOFI : drops plans for messenger RNA vaccine against virus
AQ
09/28Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vacc..
GL
09/27SANOFI : - Availability of the Q3 2021 Memorandum for modelling purposes
AQ
09/27SANOFI : New research presented at IDWeek 2021 reinforces Sanofi's robust vaccines pipelin..
PU
09/24SANOFI : Availability of the Q3 2021 Memorandum for modelling purposes
AQ
09/23SANOFI : New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-..
PU
09/21SANOFI : New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-..
AQ
09/20SANOFI : - ESMO late-breaking data show Libtayo (cemiplimab) and chemotherapy first-line t..
AQ
09/19SANOFI : ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line tr..
AQ
09/15TRANSLATE BIO : LifeSci Index Partners
AQ
09/14SANOFI : completes acquisition of Translate Bio, accelerating the application of mRNA in n..
PU
09/14SANOFI : completes acquisition of Translate Bio, accelerating the application of mRNA in n..
AQ
09/10SANOFI : provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pe..
PU
09/09SANOFI : provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pe..
GL
09/08SANOFI : to acquire Kadmon to further strengthen growth of transplant business (Form 6-K)
PU
09/08SANOFI : to acquire Kadmon to further strengthen growth of transplant business
AQ
09/03SANOFI : Dupixent® (dupilumab) efficacy and quality of life data in asthma patients across..
PU
09/01ACURX PHARMACEUTICAL'S IS DISRUPTIVE : Acxp)
AQ
08/30SANOFI : Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints bec..
GL
08/26Acurx Pharmaceuticals Plan To Change The Antibiotics Landscape Is Simple- Make Better D..
AQ
08/17Acurx Pharmaceutical's On Pace To Change The Antibiotics Landscape; Trial Data Shows 10..
AQ
08/12SANOFI : Corrective to Aug. 10 story on Moderna building a production plant in Canada
AQ
08/12DRUG MAKERS OVERSEAS ARE GAINING A C : Acxp)
AQ
08/09GRAM POSITIVE BACTERIAL INFECTIONS C : Acxp)
AQ
08/06SANOFI : FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment ..
GL
08/06SANOFI : - Phase 3 trial of Libtayo combined with chemotherapy stopped early due to signif..
AQ
08/06SANOFI : Bionity - Sanofi to acquire Translate Bio
AQ
08/06TRANSLATE BIO : Announces Second Quarter 2021 Financial Results and Provides Corporate Upd..
AQ
08/05SANOFI : Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early d..
GL
08/04SANOFI : to acquire Translate Bio, advances deployment of mRNA technology across vaccines ..
AQ
08/03SANOFI : to acquire Translate Bio; advances deployment of mRNA technology across vaccines ..
PU
08/03SANOFI : Online availability of Sanofi's half-year financial report for 2021 (Form 6-K)
PU
08/03SANOFI : to acquire Translate Bio; advances deployment of mRNA technology across vaccines ..
GL
07/30REGENERON PHARMACEUTICALS : Dupixent significantly improved itch and hives in patients wit..
AQ
07/29AMGEN : Federal Circuit Emphasizes High Bar For Enablement Of Functional Claims
AQ
07/29SANOFI : Online availability of Sanofi's half-year financial report for 2021
GL
07/29SANOFI : Sales growth accelerated - Full-year guidance raised (Form 6-K)
PU
07/29SANOFI : Q2 Earnings Snapshot
AQ
07/29SANOFI : appoints new leaders to Executive Committee and announces future Chair of EUROAPI
GL
07/29SANOFI : Sales growth accelerated - Full-year guidance raised
GL
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on SANOFI